Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/7541
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrayogi, Syaiful-
dc.contributor.authorAsrining Dhiani, Binar-
dc.contributor.authorDjaliasrin Djalil, Asmiyenti-
dc.date.accessioned2024-11-08T01:56:38Z-
dc.date.available2024-11-08T01:56:38Z-
dc.date.issued2023-04-30-
dc.identifier.issn25808303-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/7541-
dc.description.abstractAbstract Background: Although a SARS-CoV-2 vaccine is readily available, new cases of COVID-19 are still occurring. New drug discovery is needed to treat COVID-19. Protein E is one of the potential targets. Two synthetic compounds of bicycloproline derivatives have the potential to be developed. Objective: This study aimed to estimate the interaction of bicycloproline compounds to protein E in-silico. Methods: There were two bicycloproline-derived compounds, MI-09 and MI-30, used in docking. Remdesivir was used as a reference ligand. The crystal structure of the E protein was created using homology modeling, while the test compound was drawn using the Marvin Sketch. MOE 2022.02 and BDS 2021 were used for docking and visualization processes. Results: The pentamer of the SARS-CoV-2 E protein obtained a clash score (1.06); poor rotatomer (0.00%); favored rotamers (98.11%); Ramachandran favored (96.43%); Ramachandran outlier (1.78%); Rama Z-score (-1.08); and mol probity (1.04). Research shows promising inhibition potential of the MI-09 and MI-30. The MI-30 has the best binding energy of -10.3326 kcal/mol. Conclusion: The docking results show that MI-30 has potency as an inhibitor of protein E and can be developed in treating COVID-19. Further research is needed to confirm the result by in vitro and in vivo studies. Keywords: Abstract Background: Although a SARS-CoV-2 vaccine is readily available, new cases of COVID-19 are still occurring. New drug discovery is needed to treat COVID-19. Protein E is one of the potential targets. Two synthetic compounds of bicycloproline derivatives have the potential to be developed. Objective: This study aimed to estimate the interaction of bicycloproline compounds to protein E in-silico. Methods: There were two bicycloproline-derived compounds, MI-09 and MI-30, used in docking. Remdesivir was used as a reference ligand. The crystal structure of the E protein was created using homology modeling, while the test compound was drawn using the Marvin Sketch. MOE 2022.02 and BDS 2021 were used for docking and visualization processes. Results: The pentamer of the SARS-CoV-2 E protein obtained a clash score (1.06); poor rotatomer (0.00%); favored rotamers (98.11%); Ramachandran favored (96.43%); Ramachandran outlier (1.78%); Rama Z-score (-1.08); and mol probity (1.04). Research shows promising inhibition potential of the MI-09 and MI-30. The MI-30 has the best binding energy of -10.3326 kcal/mol. Conclusion: The docking results show that MI-30 has potency as an inhibitor of protein E and can be developed in treating COVID-19. Further research is needed to confirm the result by in vitro and in vivo studies. Keywords: COVID-19, homology modeling, envelope protein, bicycloproline, molecular dockingen_US
dc.publisherFaculty of Pharmacy Univesrsitas Airlanggaen_US
dc.subjectCOVID-19,en_US
dc.subjecthomology modeling,en_US
dc.subjectenvelope protein,en_US
dc.subjectbicycloproline,en_US
dc.subjectmolecular dockingen_US
dc.titleMolecular Docking of Bicycloproline Derivative Synthetic Compounds on Envelope Protein: Anti-SARS-CoV-2 Drug Discoveryen_US
dc.typeArticleen_US
Appears in Collections:VOL 10 NO 1 2023

Files in This Item:
File Description SizeFormat 
11-21.pdf952.77 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.